Welcome to Cytochroma

Dr. Lewis is the President and Chief Executive Officer of the Juvenile Diabetes Research Foundation as of January 2009. Previously, Dr. Lewis served as President, Chief Executive Officer, and Director of Novocell, Inc. since February 2006. Prior to Novocell, Dr. Lewis served as CEO and Director of Signal Pharmaceuticals before its acquisition in 2000 by Celgene, a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for cancer and immunological diseases. He then served as President of the Signal Research Division at Celgene. Dr. Lewis previously held the position of Vice President of Research at Wyeth-Ayerst, where he spent 15 years leading research efforts in diabetes, CNS, cardiovascular, inflammatory, allergy, and bone metabolism diseases. Dr. Lewis also currently serves as a Director of BioMarin Pharmaceutical, Inc., and BIOCOM. He holds a Ph.D. in pharmacology from the University of Wales in Cardiff and completed his postdoctoral training at Yale University.

Dr. Bishop has served as President and CEO of Cytochroma since June 2006, bringing a wealth of management experience in the pharmaceutical industry across multiple disciplines including Research & Development, Regulatory Affairs, Operations, and Business Development. Dr. Bishop co-founded Proventiv Therapeutics, LLC in September 2005 where he served as President. Proventiv Therapeutics, LLC was acquired by Cytochroma Holdings ULC in June 2006. During the period of September 1987 to June 2005, Dr. Bishop held various senior management positions at Bone Care International, Inc., a public specialty pharmaceutical company focused on developing and commercializing vitamin D hormone therapies. Dr. Bishop’s positions with Bone Care included President, CEO, Director, Executive Vice President of Research and Development, and Chief Scientific Officer. Under Dr. Bishop's direction, Bone Care advanced a portfolio of proprietary vitamin D hormones and analogs to varying stages of development for SHPT, metabolic bone disease, psoriasis and cancers of the prostate, breast and colon. Dr. Bishop was responsible for the successful preparation and prosecution of three NDAs that ultimately led to FDA approval of a novel vitamin D drug, named doxercalciferol, for SHPT in dialysis patients (Hectorol® 2.5 mcg Capsules and Hectorol® Injection) and pre-dialysis patients (Hectorol® 0.5 mcg Capsules). Prior to joining Bone Care, Dr. Bishop held various management positions in the Health Care Division of the Procter & Gamble Company. Dr. Bishop completed a four-year National Institutes of Health Postdoctoral Fellowship in vitamin D Biochemistry at the University of Wisconsin-Madison and received his Ph.D. degree in Nutritional Biochemistry from Virginia Polytechnic Institute and State University, after earning an undergraduate degree in Chemistry from the University of Virginia.

Dr. Kiso joined Tanabe Seiyaku Co., Ltd. in 1982, where he served in managerial positions across Product Development, R&D Planning, and Corporate Development & Licensing. He has been General Manager, Business Development & Licensing Department, at MTPC since October 2007. Dr. Kiso received his MSc from Kyoto Pharmaceutical University, an MBA from Kobe University, and a Ph.D. from Nagoya University School of Medicine.

Dr. Marengère joined VenGrowth Capital Management Inc. in 2001, and has since led the growth and management of the VenGrowth Advanced Life Sciences Fund. He brings a comprehensive knowledge of many therapeutic areas, as well as breadth of strategic expertise in the biotechnology industry. During the last 10 years Dr. Marengère has worked with a broad range of opportunities and was involved in positioning many of those companies towards financial exits. Dr. Marengère possesses extensive sector-specific transactional experience. Dr. Marengère also conducted commercial research at Amgen in the fields of immunology and oncology. Dr. Marengère has served as a Director on Boards of the Company and Canadian-based companies and is currently a Director on the Boards of Aegera Therapeutics Inc., Z-Tech Canada Inc., Trillium Therapeutics Inc. and Cytochroma Inc. Dr. Marengère holds a Ph.D. in Medical Biophysics and Molecular Genetics from the University of Toronto.

Joseph Regan, MBA
Director

Mr. Regan is a Vice President, Investments at GrowthWorks Capital. Joe joined GrowthWorks in early 2003, bringing 15 years of life sciences venture capital and pharmaceutical industry experience. He has been active in both company creation and the strategic growth of portfolio companies. Joe brings a wealth of knowledge to numerous GrowthWorks’ investee Boards, including Targeted Growth Inc., Aegera Therapeutics Inc., Viron Therapeutics Inc., Cytochroma Inc., Receptor Therapeutics Inc., Sampling Technologies Inc. and Dynacon Inc. Additionally he manages and Chairs the Sunnybrook Working Ventures Medical Breakthrough Fund. Joe has an Honours BSc (with distinction) from the University of Guelph and an MBA (Dean's List) from McMaster University.

Ulrik Spork, MSc
Director

Mr. Spork led the establishment of the new venture investment activities in Novo A/S at its start in 1999 and is since then Senior Partner in Novo Ventures. Prior to the formation of Novo A/S, Ulrik spent nine years in Novo Nordisk A/S, from 1994 as director of Corporate Development. In this capacity he was involved in that corporation’s strategy building and restructuring process and managed a number of acquisitions and divestments. Furthermore he was in charge of Novo Nordisk's equity investments in biotech companies and spinouts, including the 150 MUSD private placement in ZymoGenetics, Inc. Before joining Novo Nordisk, Ulrik spent seven years within the Vickers Plc Group, engaged in product development, international marketing and business development in the health care area. Ulrik Spork received his MSc in Engineering from the Technical University of Copenhagen in 1984, holds a BSc in International Economics from 1991 and has attended supplementary courses both within the Novo Group and at institutions such as Harvard and Stanford Business School. He presently serves on the board of directors of Celltrix AB and Light Sciences Oncology, Inc., and is a former director of CardioOptics, Inc., Corus Pharma, Inc., Novexel S.A. and BioImage A/S. In addition, he is deputy chairman of the Danish Venture Capital and Private Equity Association (DVCA).